Company Encyclopedia
View More
name
Maze Therapeutics
MAZE.US
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc.
4.498 T
MAZE.USMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking126/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-213.81%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-100.00%E
    • Net Profit YoY-455.45%E
    • Total Assets YoY119.27%A
    • Net Assets YoY281.84%A
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio10.10%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Maze Therapeutics shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised the price target from $50 to $60.

    benzinga_article·
    US
    MAZE
    -1.27%
    benzinga_article·
    US
    MAZE
    -1.27%

    Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE

    Virtus Investment Advisers LLC invested $85,000 in Maze Therapeutics, acquiring 6,940 shares. Other institutional investors have also recently taken positions in the company. Analysts have given Maze Therapeutics a consensus "Buy" rating, with a target price of $38.57. The company's stock opened at $37.75, with a market cap of $1.82 billion. Maze Therapeutics focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases.

    Market Beat·
    US
    MAZE
    -1.27%
    US
    VRTS
    +2.34%
    Market Beat·
    US
    MAZE
    -1.27%
    US
    VRTS
    +2.34%

    Raymond James Initiates a Buy Rating on Maze Therapeutics, Inc. (MAZE)

    Raymond James analyst Martin Auster initiated coverage on Maze Therapeutics, Inc. with a Buy rating and a $48.00 price target. Auster, a 4-star analyst, has an average return of 15.9% and a 50.29% success rate. H.C. Wainwright also maintained a Buy rating with a $50.00 price target. Auster covers the Healthcare sector, focusing on stocks like Ascendis Pharma and BridgeBio Pharma.

    Tip Ranks·
    US
    MAZE
    -1.27%
    Tip Ranks·
    US
    MAZE
    -1.27%

    Maze Therapeutics Reports Strong Q3 2025 Progress

    Maze Therapeutics, Inc. reported strong Q3 2025 progress, highlighting significant advancements in its clinical pipeline, including promising data for the MZE782 program and ongoing enrollment in the Phase 2 HORIZON trial for MZE829. The company maintains a robust cash position of $383.9 million, ensuring operational funding into 2028. Despite a net loss of $30.1 million for the quarter, Maze's strategic financial maneuvers have strengthened its balance sheet, positioning it well for future milestones in developing precision medicines for kidney and metabolic diseases.

    Tip Ranks·
    US
    MAZE
    -1.27%
    Tip Ranks·
    US
    MAZE
    -1.27%

    Maze Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MAZE
    -1.27%
    LB filings·
    US
    MAZE
    -1.27%
    © 2025 Longbridge｜Disclaimer